European Biotechnology in 2019 and Beyond: What’s Hot and What’s Not?
We spend a lot of time focusing on specific developments in biotechnology, but sometimes it's…
We spend a lot of time focusing on specific developments in biotechnology, but sometimes it's…
The positive stance of the UK Government towards incorporation of genomics into healthcare has created…
The Czech biotech company Sotio has shown in a phase II trial that its cellular…
The human immune system is highly complex. Not only is it made up of millions…
In 2018, there were approximately 3,400 active agents in the immuno-oncology pipeline, a 67% increase…
The Swiss biotech Anaveon closed a very respectable €31M (CHF35M) Series A fundraising round to…
The UK biotech Grey Wolf Therapeutics has raised €11.4M (£10M) to fuel the development of…
Research on immunotherapies against cancer dates back over a century ago, when Paul Ehrlich hypothesized…
Update (01/02/2019): MorphoSys has agreed to end its long-running legal battle with Genmab and Janssen, after…
A European trial has proved the feasibility and efficacy of treating cancer with a personalized…
In recent years the oncology world has focused on using the immune system to target…
The field of immuno-oncology promises to make anti-cancer treatments more effective than ever. But in…